Given the limited understanding of mitotic DSB repair mechanisms and the ongoing clinical trials targeting Polθ, defining the precise role of the CIP2A-TOPBP1 axis in DNA repair is critical for improving the treatment of cancers. This evidence concerns the gene TOPBP1 and cancer.